ERS international congress 2020: highlights from the “Clinical techniques, imaging and endoscopy” assembly

Pia Iben Pietersen, Bibi Klap, Nicole Hersch, Christian B. Laursen, Simon Walsh, Jouke Annema, D. Gompelmann

Please cite this article as: Pietersen PI, Klap B, Hersch N, et al. ERS international congress 2020: highlights from the “Clinical techniques, imaging and endoscopy” assembly. *ERJ Open Res* 2021; in press (https://doi.org/10.1183/23120541.00118-2021).

This manuscript has recently been accepted for publication in the *ERJ Open Research*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

Copyright ©The authors 2021. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
ERS International congress 2020: highlights from the „Clinical techniques, imaging and endoscopy“ assembly

Pia Iben Pietersen 1,2, Bibi Klap3, Nicole Hersch4, Christian B Laursen1,5, Simon Walsh6, Jouke Annema3, D Gompelmann7,8

1 Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark
2 Regional Center for Technical Simulation, Region of Southern Denmark, Odense, Denmark
3 Department of Respiratory Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
4 Department of Respiratory Medicine, St George Hospital, Sydney, Australia
5 Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
6 National Heart and Lung Institute, Imperial College, London, UK
7 Department of Internal Medicine II, Division of Pulmonology, Medical University of Vienna, Vienna, Austria
8 Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria

Address correspondence to:
Prof. Dr. med. Daniela Gompelmann
Department of Internal Medicine II, Division of Pulmonology
Medical University of Vienna
Währinger Gürtel 18-20
1090 Vienna
Vienna, Austria
“Take home” message

This manuscript summarises the development in interventional pulmonology, imaging techniques and ultrasound presented at the ERS Congress in 2020. Novel diagnostic and therapeutic approaches in various lung diseases are presented.
Abstract

The European Respiratory Society (ERS) congress in the year 2020, a year dominated by the SARS-CoV-2 pandemic, was the first virtual congress that was ever planned with an innovative and interactive congress programme upfront. It was a large, novel platform for scientific discussion and presentations of cutting-edge innovative developments. This manuscript summarises a selection of the scientific highlights from the “Clinical techniques, imaging and endoscopy” Assembly 14. In addition to presentations on the important role of bronchoscopy, imaging and ultrasound techniques in the field of SARS-CoV-2 infection, novel diagnostic approaches and innovative therapeutic strategies in patients with lung cancer, interstitial lung disease, obstructive airway disorders and infectious diseases were also discussed.
Key topics at the first virtual ERS International Congress 2020 included novel diagnostic and therapeutic approaches in patients with SARS-CoV-2 infection, lung cancer, interstitial lung disease, obstructive airway disorders and infectious diseases. The authors from the different Assembly 14 subgroups focus on the key take-home messages given new study results and place them in the context of the current knowledge in these areas.

**Group 14.01: interventional pulmonology**

**CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

Targeted Lung Denervation (TLD) is a novel endoscopic treatment for patients with symptomatic chronic obstructive pulmonary disease (COPD), which aims to disrupt the parasympathetic nerves around the main bronchi by radiofrequency ablation [1].

At the ERS congress in 2018, Slebos et al. presented data from a randomised sham-controlled double-blinded multicentre trial showing the feasibility and safety of this treatment in patients with moderate-to-severe COPD [2]. In 2019, the AIRFLOW-2 study group published an article where the safety of TLD was prospectively evaluated, with the effect on respiratory adverse events as the primary outcome. The risk of COPD exacerbation requiring hospitalisation in the 12.5-month follow-up was significantly lower in the TLD group than in the sham group [3]. At ERS 2020, Shah et al. presented the AIRFLOW-2 crossover patient outcomes whereby, following the 12-month follow-up visit, patients in the sham group were also offered TLD treatment (crossover group). Acute COPD exacerbations (AECOPD) and lung function was then analysed in these 20 crossover patients. Fifteen patients had completed 12-month follow-up. The percentage of patients with a moderate or severe AECOPD and severe AECOPD alone following TLD decreased from 73% to 47% and 25% to 13%, respectively. Time-to first event for moderate and severe AECOPD, and severe AECOPD was also attenuated by TLD [4].

Frequent COPD exacerbations lead to a more rapid decline in lung function. As TLD reduces the number and severity of COPD exacerbations, Hartman et al. studied the annual decline in FEV1 before and up to 3 years after TLD. In fourteen patients treated with TLD, the annual decline in FEV1 was significantly less compared to before treatment (n=11; mean FEV1 decline 1 year before treatment -57mL per year vs n=14; mean FEV1 decline 3 years after treatment -24mL per year) [5]. The large clinical trial including a control group with 5 year follow up (AIRFLOW-3), currently underway, will be needed to confirm these results.
A different treatment modality for COPD is endoscopic lung volume reduction (ELVR) with endobronchial valves. Previous studies have shown good clinical outcomes in selected COPD patients so that valve treatment is also recommended as additional therapy in patients with advanced emphysema in the GOLD recommendation [6]. Due to a high postoperative mortality rate reported in an earlier surgical trial [7] in the high-risk COPD group, patients with a transfer factor of the lung for carbon monoxide (TLCO) of <20% have usually been excluded from ELVR trials. Lenga et al. presented outcomes (lung function, quality of life and exercise capacity) in relation to the TLCO of patients treated with ELVR. 34 patients with a TLCO <20% and 87 patients with a TLCO >20% were included. They found a significant improvement in clinical outcomes 3 months after ELVR in patients with a low TLCO. This data indicates that the treatment response after ELVR might be also beneficial for patients with a low TLCO [8].

Severity of hyperinflation is one of the key factors for success of ELVR with valves. Prior multicentre randomised controlled trials (RCT) excluded patients with a residual volume (RV) ≤175%. Klooster et al. included 12 patients in a single-centre retrospective study with an RV ≤175% and a clear target lobe. Lung function (FEV1, RV), 6 minute walk test (6-MWT) and St. George Respiratory Questionnaire (SGRQ) improved at both 1 and 6 months after ELVR [9].

A systematic comparison of surgical lung volume reduction (LVRS) and ELVR with valves is still missing. The Lung Emphysema Registry (LE-R), a multicentre non-randomised prospective clinical study collected data on patients with emphysema treated with LVRS or ELVR [10]. Since 2017, 246 patients were recruited; the surgical group (n=88) and the ELVR group (n=158) both showed significant improvements in lung function and quality of life at 3 months. Both techniques seem to be beneficial to patients with severe emphysema. Actually, a multicentre RCT - CELEB trial - is performed that compares the outcomes 1 year between LVRS and ELVR. Hopefully, this RCT and future studies, including safety data, might help to define which patient subgroup should be treated with LVRS or ELVR.

Chronic hypercapnic failure (CHF) may develop in patients with severe emphysema and hyperinflation. Previous analysis showed improvement in lung function as well as hypercapnia in patients treated with ELVR [11]. In a retrospective trial presented at the ERS 2020, 138 emphysema patients with CHF (pCO2 ≥ 45 mmHg) and treated with ELVR were enrolled. A significant decrease in mean pCO2 (pre-ELVR mean pCO2: 49.8 mmHg ±4.8) could be found at 3 months (mean pCO2: 46.1 mmHg ±12.1; p<0.001) and 6 months (pCO2: 46.4 mmHg ±18.9; p<0.001) after intervention [12]. Prospective trials are warranted.

**Take-home messages**
• TLD is a safe and effective endoscopic procedure which leads to a significantly lower risk of COPD exacerbations
• After TLD, the annual decline in FEV1 is significantly less compared to before treatment
• ELVR with endobronchial valves might be beneficial for patients with a DLCO <20%, and also for patients with less severe hyperinflation (RV <175%) in cases with a clear target lobe

LUNG CANCER
One of the biggest bronchoscopic challenges is how to diagnose small, peripheral pulmonary nodules (PPN). The number of patients with PPN that require tissue confirmation is rapidly increasing with the use of computerised chest tomography (CT) and the implementation of lung cancer screening programs. At the ERS 2020 different methods for diagnosing PPN were presented.
Transbronchial lung cryobiopsy (TBLC) is an endoscopic procedure that has proven diagnostic value for interstitial lung diseases [13], however, there is limited data investigating its use in suspected lung cancer. An observational, retrospective cohort study between 2015-2019 enrolled 512 patients who underwent TBLC for suspected lung cancer. The overall diagnostic yield was 93%. 442 cases were malignant and 70 had a non-malignant pathology with clinical and radiographic follow-up [14]. The complication rate for pneumothorax was 6.6% and for any grade of bleeding was 18%. In most procedures fluoroscopy and radial endobronchial ultrasound (EBUS) was used for navigation.
These results were confirmed by another observational study evaluating diagnostic efficacy of radial-EBUS guided TBLC of PPN in obtaining histological diagnosis and molecular subtyping [15]. Histopathology was conclusive in 41/44 (93%) patients. Molecular subtyping was able to be performed in 60% (9/15) of squamous cell carcinoma cases and in 88% (15/23) of adenocarcinoma and not otherwise specified lung cancer cases.
A late breaking abstract at the ERS 2020 evaluated the efficacy and safety of TBLC and transbronchial forceps biopsy (TBFB) in the diagnosis of PPN [16]. 39 patients were enrolled with TBFB performed in all patients (n=39) and TBLC also performed in 14 patients. Radial-EBUS and fluoroscopy was used for guidance with the probe position within the PPN in 33.3% and adjacent to the PPN in 66.7% of cases.
Diagnostic yield of TBFB, TBCB and a combined approach (TBFB+TBCB) were 64.1% (25/39), 64.3% (9/14) and 69.2% (27/39) respectively (p<0.05). The diagnostic yield was 85% (11/13) when placing the radial-EBUS probe inside the PPN. No complications occurred.
These studies show that TBLC use in PPN cases results in high diagnostic yields with an acceptable complication profile, especially when used in combination with radial-EBUS. However, the added value of TBLC should be evaluated in further randomised trials.
Virtual bronchoscopy navigation (VBN) is a diagnostic modality to access and sample PPN under fused fluoroscopic guidance. A study from Herth et al. included 116 patients with solitary pulmonary nodules ≥8mm and compared the biopsy yield and performance of VBN with or without radial-EBUS guidance [17]. Overall, biopsy yield was 94% and there was no difference in yield when radial-EBUS was used.

Another new innovative technique to diagnose PPN is needle-based confocal laser endomicroscopy (nCLE) which enables real-time microscopic analysis at the needle tip. A study presented at the ERS 2020 included 15 patients in which the feasibility and safety of nCLE-imaging for diagnosis of PPN was assessed. In 87% of patients (13/15), good to high quality videos were obtained. All malignant lesions scored at least 2/3 malignant CLE criteria [18].

EBUS combined with strain elastography might be a helpful diagnostic modality to differentiate malignant lymph nodes [19] by measuring stiffness of a lymph node with ultrasound, where the stiffer node (colouring blue) is more likely to have malignant infiltration. Teng et al. presented a prospective study which included 47 patients in which all lymph nodes > 5mm were sampled and evaluated with elastography [20]. 30 lymph nodes were scored as non-blue, of which final cytology showed only 1 malignant case. 51 lymph nodes scored mixed blue/green or blue on elastography and cytology showed malignancy in 26 cases. This resulted in a 96% sensitivity rate but 54% specificity in predicting malignancy, with a negative predictive value of 97%.

Malignant central airway obstruction occurs in ~20% of primary lung carcinomas or pulmonary metastasis [21, 22]. A novel modality using microwave ablation (MWA) to treat malignant airway obstruction was presented at the ERS 2020. MWA heats tissue by creating an electromagnetic field around an ablation device. In 5 cases successful airway recanalisation was achieved with no immediate complications noted [23]. MWA also offers the potential for local therapy in inoperable peripheral lung cancer and for patients who cannot undergo stereotactic radiation [24]. A pilot study in 13 patients showed that bronchoscopic MWA is a feasible, efficacious, and safe treatment for peripheral lung cancer (ineligible for surgery) [25]. The local control rate and complete ablation rate was 85.71 % (12/14) and 78.57% (11/14), respectively, at 6 months post-ablation.

Another diagnostic challenge can be the assessment of tumor invasion (T-status) in the mediastinum and large vessels (T4). A retrospective study included 104 patients were T-status was reviewed based on EBUS, CT and thoracotomy findings [26]. Surgical-pathological staging was gold standard with 36 patients (27.6%) diagnosed as stage pT4. EBUS showed a high specificity (84-98%) and NPV (76-88%) for T4 assessment and could be of additional value to CT alone.
**Take-home messages**

- TBLC use in suspected lung cancer cases resulted in high diagnostic yields with an acceptable complication profile, especially when radial-EBUS is within the PPN.
- Bronchoscopic nCLE-imaging of PPN is feasible and safe and has the potential to serve as a real-time guidance tool to improve lung cancer diagnostics.
- Bronchoscopic microwave ablation is a novel modality which in case series seems feasible, efficacious, and safe for the treatment of peripheral lung cancer and central airway obstruction.
- In patients with lung tumors located adjacent or near the major airways, T4 assessment by EBUS can be of added value.

**INTERSTITIAL LUNG DISEASES**

In interstitial lung diseases (ILD), transbronchial lung cryobiopsy was also a hot topic at the ERS congress 2020. TBLC is a safe alternative to surgical biopsy as shown in the COLDICE trial [27] published last year.

One study evaluated safety in 480 patients who underwent TBLC for ILD [28]. Overall, 5.6% developed pneumothorax and 15.8% required a haemostatic agent for bleeding. Patients with antiplatelet or anti-coagulant therapy or patients with emphysema had a tendency to develop pneumothorax (p<0.001 and p 0.029). The presence of emphysema as risk factor for pneumothorax following TBLC is comprehensible due to the increased vulnerability of emphysematous lung tissue. However, the antiplateled drug treatment and its association with the advent of pneumothorax is questionable. It can maybe explained by the fact, that TBLC in patients with anticoagulant therapy is performed intentionally more close to the pleura to avoid the risk of bleeding following central TBLC.

The safety of TBLC was again confirmed by Daniels et al. who showed an overall pneumothorax rate of 15.1% in 93 patients (mean number of biopsies 3.8 ±1.3) over a 5 year period [29]. Notably, the annual rate of pneumothorax declined from 29% in 2015 to 8% in 2018 and 2019, emphasising the learning curve.

The impact of various comorbidities on the safety and complications of TBLC are uncertain. A prospective study of 196 patients with comorbidities including hypertension, diabetes mellitus, ischaemic heart disease, chronic kidney disease and chronic liver disease. None of the comorbidities, alone or in combination, had a significant impact on rates of pneumothorax or bleeding [30].
Tomassetti et al. investigated whether the histological information obtained by lung biopsy (surgical or TBLC) had an impact on clinician management in 426 patients without a definite usual interstitial pneumonia (UIP) pattern. Within this trial, a multidisciplinary team made a management decision before and after lung biopsy. The results showed changes in clinical management in 147/426 cases (35%) \[^{[31]}\]. The most notable differences observed were a decrease in both the prevalence of untreated patients (from 15% to 4%, \(p<0.001\)) and in patients that would have been treated with steroids (from 54% to 37%, \(p<0.001\)). Antifibrotic and immunosuppressive use significantly increased after lung biopsy revision (from 23% to 44%, \(p<0.001\) and from 7% to 14%, \(p<0.001\), respectively). In uncertain ILD cases, lung biopsy can be of great value.

**Take-home messages**
- TBLC is a safe alternative to surgical biopsy in patients with multiple comorbidities
- In uncertain ILD cases, lung biopsy led to a change in treatment in 30% of cases

**Group 14.02: imaging**

**INTERSTITIAL LUNG DISEASE**

It is crucial to diagnose interstitial lung disease (ILD) at an early stage so that treatment can be started in time. Lung function and chest X-ray are the first steps if lung disease is suspected. However, early ILD can be missed on chest X-ray examination alone. At ERS congress 2020, one study presented data from artificial intelligence (AI) software used to help physicians detect ILDs \[^{[32]}\]. The area under the curve (AUC) of receiver operating characteristics (ROC) for the detection capability of AI was 0.979, with a sensitivity and specificity of 90% and 100% respectively, thus exceeding that of human physicians alone. Thus, this software may help to identify patients with ILD at a very early stage, providing an early start of further diagnostics and adequate treatment. However, further research is warranted.

Furthermore, the impact of magnetic resonance imaging (MRI) as an imaging method to assess ILDs was explored. One trial examined the usefulness of oxygen enhanced MRI (OE-MRI) as a novel biomarker in patients with different ILD phenotypes \[^{[33]}\]. As biomarkers, baseline T1, change in delta pO2, O2 wash-in time and ventilated volume fraction were obtained at three different timepoints and compared with lung function tests. In the subgroup of patients with idiopathic pulmonary fibrosis (IPF), T1 correlated with the diffusion capacity and the change in delta pO2 between the
different visits correlated with the change in KCO%. These positive correlations could only be observed in the IPF subgroup, but not in the other ILD subtypes.

The utility of 129-xenon diffusion imaging in ILDs is still not well understood. The apparent diffusion coefficient (ADC) and the mean diffusive length scale (Lm) is a diffusion-weighted (DW) MRI measurement that provides information about lung microstructure down to the alveolar level. In one prospective observational study, 3D DW-MRI with hyperpolarised 129-xenon was performed twice in 14 patients with IPF [34]. There was a significant longitudinal change in mean \(129\text{Xe} \text{Lm}_D\) in the lower and middle lung zones, but no significant change in ADC or lung function parameters. Thus, \(129\text{Xe} \text{Lm}_D\) may be a useful imaging biomarker to assess disease progression and can provide further insight into the lung microstructure in IPF.

**Take-home messages**

- Artificial intelligence using conventional chest x-rays may help to identify patients with ILD at an early stage
- Oxygen enhanced MRI and diffusion-weighted MRI may present useful biomarkers that assist in identifying ILD subtype and assessing ILD progression

**LUNG CANCER**

Various randomised clinical trials (RCT) including the Nederlands-Leuvens Longkanker Screenings Onderzoek (NELSON) trial and National Lung Screening trial (NLST) have demonstrated CT-based lung cancer screening to be efficacious in reducing lung cancer mortality [35; 36]. However, there are still some uncertainties leading to slow initiation of formalised lung cancer screening programs. So far, recruitment for screening is based on the inclusion criteria of the lung cancer screening trials. One trial presented at ERS congress 2020 calculated the proportion of lung cancer patients who would have been eligible for lung cancer screening under major trial inclusion criteria [37]. The authors found that only 1/3 of the lung cancer patients would have been invited for screening according to NLST and NELSON criteria. This finding reinforces that additional tools to stratify risk and facilitate earlier diagnosis are needed.

Cui and colleagues evaluated the diagnostic accuracy of a deep learning-based computer-aided detection (DL-CAD) system [38]. In this trial, 360 CT scans were retrospectively evaluated by the DL-CAD system and then independently by radiologists in a double reading fashion. An additional senior radiologist checked all the results and made the consensus as to the reference standard. The DL-CAD system achieved a sensitivity of 89.3% with one false positive per scan, while radiologists had a
sensitivity of 76.0% for detection during double reading. Thus, the DL-CAD system may assist radiologists in pulmonary nodule detection.

Take-home messages
- Deep learning-based computer-aided detection system may assist in detecting pulmonary nodules

CHRONIC OBSTRUCTIVE PULMONARY DISEASE
In recent years, radiological assessment in patients with chronic obstructive pulmonary disease (COPD) has gained importance particularly in patient selection for ELVR. CT reflects disease severity, emphysema type and distribution.

One trial presented at the congress shows that CT assessment of erector spinae muscle may predict long-term mortality of COPD patients [39]. In this prospective observational study, reduction in the cross-sectional area of erector spinae muscles (ESM$_{CSA}$), total airway count (TAC), wall area percent of the segmental airways (WA%) and airway tree to lung volume ratio (AWV%) were assessed in 247 COPD patients. Reduced ESM$_{CSA}$ was associated with poor prognosis more strongly than the other CT parameters. This finding emphasises the impact of muscle loss on survival of COPD patients and confirms the importance of preventive strategies.

Functional respiratory imaging (FRI) is another CT tool that provides an assessment of ventilation/perfusion mismatch in COPD patients [40]. Here, quantitative CT measures of lobe expansion and blood vessel volumes are obtained to evaluate ventilation/perfusion values. A pooled cohort of 96 patients were studied retrospectively and the FRI results correlated with clinical outcomes. It was shown that ventilation/perfusion levels correlated significantly with SGRQ, 6-minute walk test (6-MWT) and oxygen desaturation during 6-MWT. This finding emphasises the impact of ventilation/perfusion mismatch on clinical performance of COPD patients and underlines the importance of restoring the ventilation/perfusion level to improve patient’s clinical status.

Take-home messages
- CT assessment of erector spinae muscle loss in COPD patients predicts long-term mortality in COPD patients
- Functional respiratory imaging allows the assessment of ventilation/perfusion mismatch which correlates with COPD patient’s clinical status

CORONAVIRUS DISEASE-19
Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) dominated 2020. Infections with SARS-CoV-2 were widespread all over the world leading to a global COVID-19 public health emergency. Besides clinical features and laboratory tests, radiological assessment plays an important role in COVID-19 detection, assessment of disease severity and disease monitoring. In particular, CT reveals typical COVID-19 features of ground glass opacities, consolidation, a reticular and/or crazy-paving pattern [41]. Zerka et al. evaluated the development of a new AI software to detect COVID-19 patients [42]. This software was shown to have an accuracy of 85%, a sensitivity of 70%, a specificity of 92%, an NPV of 95% and a positive predicted value of 59.44%. Thus, this AI software seems to provide an accurate means of detecting COVID-19 patients allowing rapid, accurate diagnosis and facilitating the implementation of isolation procedures and early intervention.

Limitations of CT may include patient transport, machine preparation and scanning time, such that chest x-rays, which is more widely available, still plays an important role. However, as chest x-rays are non-specific and often difficult to interpret, a machine-learned early detection system using conventional chest x-ray to identify COVID-19 and differentiate its phenotypes was evaluated [43]. The sensitivity, positive predicted value and negative predicted value of the machine early detection system for COVID-19 was 91%, 97% and 99% respectively resulting in a diagnostic accuracy of 95%. This encouraging result demonstrates that a machine-learned early detection system using conventional chest x-ray can identify unique features of COVID-19 facilitating fast diagnosis.

Another trial evaluated the impact of chest x-ray as predictor of prognosis in COVID-19 [44]. Chest X-rays in 595 patients with symptoms suggestive of COVID-19 were retrospectively analysed and correlated with ICU (intensive care unit) admission, continuous positive airway pressure (CPAP) use, swab positivity and mortality. It showed that in those with COVID-19, a normal chest X-ray was a statistically significant negative predictor for ICU admission, CPAP use, mortality, and swab positivity (p<0.05).

**Take-home messages**

- Artificial intelligence software using CT scans or chest X-rays provides identification of COVID-19 patients
- A normal chest X-ray in COVID-19 patients admitted to hospital seem to be associated with a reduced risk of mortality

**Group 14.03: ultrasound**
CORONAVIRUS DISEASE-19

The SARS-CoV-2 pandemic has changed the need for rapid evaluation and bedside imaging assessment in order to narrow differential diagnoses without compromising patient and health care worker safety, and to limit potential spread of the virus. Due to the increased number of patients in need of supportive care and thereby limited resources, it is of great importance to be able to stratify patients who will experience more mild or severe disease.

Thoracic ultrasound was explored as a tool for predicting severity and clinical outcomes in COVID-19 patients [45]. The authors used a 0-36-point system (12 scanning zones), and found with a cut-off score of 24 points, a sensitivity of 100%, specificity of 69.2%, and AUROC was 0.846 for identifying patients with a worse prognosis (defined as ICU admission or death within 14 days).

The sonographic findings interpreted as COVID-19 were few B-lines (1 point), multiple B-lines (2 points), or consolidation (3 points). No studies have explored this to date, but the prediction by the experienced ultrasound operators in the ERS assembly is that a high correlation is likely. More studies are expected to be published in this area over the next year leading to a more solid and comprehensive pool of data at ERS 2021.

Take-home messages
- Ultrasonography may be used to assess lung involvement in COVID-19 patients.
- The evidence for the use of ultrasound as a screening tool for persistent post-COVID-19 parenchymal abnormalities is sparse.

SUSPECTED MALIGNANT LUNG LESIONS AND MALIGNANT PLEURAL EFFUSION

The evidence for lung cancer screening programmes is increasing [46]. More clinical studies and potential implementation of nation-based screening programs will without doubt lead to a higher number of interventional procedures in the diagnostic work-up of pulmonary nodules. Transthoracic ultrasound-guided biopsies have gained attention because of fewer complications compared to e.g., CT-guided transthoracic biopsies of peripheral and subpleural lesions.

Sharshar et al. presented a study exploring the diagnostic yield and complication rate of ultrasound-guided transthoracic needle biopsies [47]. The results, showing a diagnostic yield of 80% and complication rate of 6.66% for pneumothorax and 3.33% for pulmonary haemorrhage, are supported by a systematic review and meta-analysis of the same topic [48].
Non-invasive methods for the investigation of lung nodules are warranted, especially in patients with co-morbidities or reduced lung function. Transthoracic shear wave elastography has been explored but so far it is not able to distinguish between benign and malignant lung nodules nor between different histological types of lung cancer [49]. It may be influenced by conditions such as fibrosis, necrosis, air in the surrounding lung parenchyma and pleural effusion.

Ultrasound has a high diagnostic accuracy for the detection of pleural effusion [50]. The presence of pleural effusion most often leads to a cytological examination to rule in or rule out malignancy, but first cytological evaluation implies a sensitivity of only 60% [51]. A systematic review and meta-analysis investigated whether thoracic ultrasound can identify and rule-in malignant pleural effusion (MPE) [52]. The ultrasound findings were not useful in the diagnostic work-up of suspected MPE, however, pleural nodularity in conjunction with pleural effusion could be used as a rule-in test for proceeding with repeated thoracocentesis or additional invasive procedures when malignant disease is suspected.

A systematic review of the current clinical application of contrast-enhanced thoracic ultrasound revealed that its use to guide transthoracic biopsies could increase diagnostic accuracy by 14.6% on average [53]. However, the use of contrast-enhanced ultrasound to distinguish between benign or malignant lesions is not yet well supported by evidence, as the studies were overall heterogeneous, small and with high risk of bias. This reinforces the need for larger, controlled studies before the true application of contrast-enhanced ultrasound can be assessed.

**Take-home messages**

- Ultrasound-guided transthoracic biopsy of peripheral lesions is feasible and has a high diagnostic accuracy and an acceptable complication rate
- In patients with suspected malignant pleural effusion, ultrasound findings of pleural nodularity warrant further invasive procedures
- More studies on advanced ultrasound modalities (e.g., contrast-enhanced thoracic ultrasound, elastography) are needed to determine their role in the work-up of pulmonary lesions

**DIAPHRAGM**

The amount of literature that investigates the sonographic assessment of respiratory musculature has exploded within the last two years, with the most commonly evaluated muscle being the diaphragm [54]. The most frequent outcome measures for diaphragmatic function were diaphragm thickness, thickening fraction and excursion, with patients more frequently assessed in the supine position.
position and with an intercostal view. However, the real clinical utility of ultrasound for diaphragm assessment is still debated.

In relation to MPE, fluid drainage normally reduces most patients’ respiratory symptoms. Evidence as to whether pre-drainage motility of the diaphragm can predict the symptomatic outcome has been explored; in a small study (n=20 patients), ultrasound examination of the diaphragmatic shape prior to the pleural procedure did not predict how well the patients felt post-procedure, but excursion may be able to predict the response [55]. Even though many studies have been presented within this topic the last few years, there still remains a gap in the evidence that needs to be explored further [56].

**Take-home message**

- Many studies have explored the role of ultrasound in diaphragmatic assessment, but the evidence is divergent and heterogenous, and there is a in need for standardised definitions, scanning protocols and larger, more uniform studies.

**ULTRASOUND IN CHILDREN**

In adult pulmonology, emergency medicine, and critical care, ultrasound is widely implemented with a solid evidence base [57, 58]. In a paediatric setting the evidence is less prominent but increasing since the examination does not, for example, expose children to radiation or require movement to another room. Compared to conventional chest x-ray, ultrasound has a high sensitivity (97%) and specificity (96%) for the detection of pneumonia in children [59]. Additionally, the sonographic consolidation dimension (measured on the largest consolidation surface) correlates with the serum C-reactive protein level. Despite the limited number of patients (n=49), one study suggested ultrasound as a tool for monitoring hospitalised infants and children [60]. In accordance with published literature, the presented abstracts further indicate that ultrasound may replace chest x-ray as the first line imaging modality in children with suspected pneumonia [61].

Another major topic that many researchers have explored but which is not yet well anchored is the role of ultrasound in diagnosing or monitoring ILDs. A pilot study of five children was presented exploring the feasibility of ultrasound and comparability of thoracic ultrasound and CT images [62]. The preliminary results demonstrated good correlation between the images. This result supports the main findings in one adult ILD-study comparing ultrasound and HRCT [63] but differs from another which also explores ultrasound elastography for diagnosing and follow-up of ILD [64].

**Take-home messages**
Ultrasound is an acceptable diagnostic tool for identifying pneumonia in children and potentially for monitoring purposes as well.

Like in adults, the evidence for ultrasound in relation to ILD is divergent. So far, it is not possible to confirm how ultrasound should be used.

EDUCATION & TRAINING

The increased interest, use, and research in thoracic ultrasound has provoked an increased interest in educational approaches. Despite a steep learning curve, implementation of point-of-care ultrasound without simultaneous implementation of a structured, competency-based training programs is a hazard to patient safety [65]. A regional survey revealed that 72% of residents had performed thoracic ultrasound or done unsupervised pleural procedures before being a level 1 practitioner despite the Royal College of Radiologists’ recommendations [66]. Half of residents had access to organised education and training of pleural skills, but only half responded that they had access to supervision for difficult procedures [67]. Even though training programs are provided at a European and, in several countries, at a national level, there is plenty of room for improvement – all the way down to an institutional level, focus on competence should be prioritised [68].

In order to improve safety and reduce complications following pleural procedures, the British Thoracic Society has published safety standards for invasive procedures [69]. A study among respiratory registrars found that these checklists are not used enough but that they are more likely to be used if they are available in a dedicated procedure room or next to the procedural equipment [70].

During an oral session on skills training in the field of respiratory medicine, the limited access to education and skills training due to COVID-19 restrictions was highlighted, as this is an immediate and direct threat to patient safety. Development of innovative methods for ensuring high quality and evidence-based education and skills training in setting with COVID-19 restrictions should be a high priority.

Take-home messages

- As the role of thoracic ultrasound increases, there is higher demand for structured training programmes and organised supervision in clinical settings
- More studies are warranted to explore the daily practices of education and supervision
- Goal-directed efforts should be made to ensure education and skills training is still possible despite COVID-19 restrictions
REFERENCES

[1] Slebos DJ, Klooster K, Koegelenberg CF, Theron J, Styen D, Valipour A, Mayse M, Bolliger CT. Targeted lung denervation for moderate to severe COPD: a pilot study. Thorax 2015: 70(5): 411-419.

[2] Slebos DJ, Shah P, Herth F. A double-blind, randomized, sham-controlled study of targeted lung denervation in patients with moderate to severe COPD. Eur Respir J 2018: 52: Suppl. 62, OA 4929.

[3] Slebos DJ, Shah PL, Herth FJF, Pison C, Schumann C, Hubner RH, Bonta PI, Kessler R, Gesierich W, Darwiche K, Lamprecht B, Skowasch D, Deslee G, Marceau A, Sciurba FC, Gosens R, Hartman JE, Srikanthan K, Duller M, Valipour A, Group A-S. Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial. Am J Respir Crit Care Med 2019: 200(12): 1477-1486.

[4] Shah P, Valipour A, Pison C, Schumann C, Bonta P, Kessler R, Gesierich W, Darwiche K, Lamprecht B, Skowasch D, Slebos D. Targeted lung denervation in patients with moderate to severe COPD: AIRFLOW-2 crossover patient outcomes. Eur Respir J 2020. 56 (suppl 64): 3775.

[5] Hartman J, Augustijn S, Klooster K, Ten Hacken N, Slebos D. Pre-treatment lung function decline stabilizes up to 3 year after targeted lung denervation in COPD. Eur Respir J 2020. 56 (suppl 64): 3776.

[6] Klooster K, ten Hacken NH, Hartman JE, Kerstjens HA, van Rikxoort EM, Slebos DJ. Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. N Engl J Med 2015: 373(24): 2325-2335.

[7] Naunheim KS, Wood DE, Krasna MJ, DeCamp MM, Jr., Ginsburg ME, McKenna RJ, Jr., Criner GJ, Hoffman EA, Sternberg AL, Deschamps C, National Emphysema Treatment Trial Research G. Predictors of operative mortality and cardiopulmonary morbidity in the National Emphysema Treatment Trial. J Thorac Cardiovasc Surg 2006: 131(1): 43-53.

[8] Lenga P, Grah C, Ruwwe-Glösenkamp C, Rücker J, Pfannschmidt J, Eggeling S, Kurz S, Leschber G, Schmidt B, Schneider P, Gebhardt A, Becke B, Hübner R. Endoscopic lung volume reduction with endobronchial valves in very low DLCO patients. Eur Respir J 2020. 56 (suppl 64): 3778.

[9] Klooster K, Hartman J, Slebos D. Endobronchial valves for emphysema are effective in patients with moderate hyperinflation in the presence of a clear target lobe. Eur Respir J 2020. 56 (suppl 64): 875.

[10] Lenga P, Grah C, Rücker J, Pfannschmidt J, Eggeling S, Kurz S, Leschber G, Schmidt B, Schneider P, Gebhardt A, Becke B, Hübner R. Outcome of surgical and endoscopic lung volume reduction with valves in patients with severe lung emphysema: current data of 246 patients with 3 months follow-up from a Lung Emphysema Registry in Germany. Eur Respir J 2020. 56 (suppl 64): 4095.

[11] Simon M, Harbaum L, Oqueka T, Kluge S, Klose H. Endoscopic lung volume reduction coil treatment in patients with chronic hypercapnic respiratory failure: an observational study. Ther Adv Respir Dis 2017: 11(1): 9-19.

[12] Rötting M, Polke M, Kriegsmann K, Sarmand N, Eberhardt R, Herth F, Gompelmann D. Impact of endoscopic valve therapy on hypercapnia in patients with chronic hypercapnic failure based on a severe lung emphysema. Eur Respir J 2020. 56 (suppl 64): 3777.
[13] Hetzel J, Maldonado F, Ravaglia C, Wells AU, Colby TV, Tomassetti S, Ryu JH, Fruchter O, Piciucchi S, Dubini A, Cavazza A, Chilosi M, Sverzellati N, Valeyre D, Leduc D, Walsh SLF, Gasparini S, Hetzel M, Hagmeyer L, Haentschel M, Eberhardt R, Darwiche K, Yarmus LB, Torrego A, Krishna G, Shah PL, Annema JT, Herth FJF, Poletti V. Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. Respiration 2018: 95(3): 188-200.

[14] Herth F, Sun J, Mayer M, Herth J, Eberhardt R, Kontogianni K, Yarmus LB. Value of Transbronchial Lung Cryobiopsy in Patients Suspicious of Peripheral Lung Cancer. Eur Respir J 2020. 56 (suppl 64): 3779.

[15] Gnass M, Sola J, Orzechowski S, Lis M, Skrobot M, Pankowski J, Bartczak A, Szlubowski A. Transbronchial lung cryobiopsy guided radial mini-probe EBUS for diagnosing peripheral lung lesions suspected of malignancy. Eur Respir J 2020. 56 (suppl 64): 1578.

[16] Ankudavicius V, Zemaitis M, Milliauskas S. Late Breaking Abstract - Radial endobronchial ultrasound guided transbronchial cryobiopsy with fluoroscopy in the diagnosis of peripheral pulmonary nodule: first experience in the Hospital of LUHS Kauno klinikos. Eur Respir J 2020. 56 (suppl 64): 1186.

[17] Herth F, Vachani A, Criner G, Li S, Nader D, Kopas L, Wahidi M, Majid A, Sun J. Multicenter, Prospective Trial: Comparing Yield and Performance of Virtual Bronchoscopic Navigation With and Without Radial-EBUSF. Eur Respir J 2020. 56 (suppl 64): 3475.

[18] Kramer T, Wijmans L, De Bruin M, Bonta P, Annema J. Bronchoscopic needle based confocal laser endomicroscopy (nCLE) as a real-time detection tool for peripheral lung cancer. Eur Respir J 2020. 56 (suppl 64): 5127.

[19] Korrungruang P, Boonsarngsuk V. Diagnostic value of endobronchial ultrasound elastography for the differentiation of benign and malignant intrathoracic lymph nodes. Respirology 2017: 22(5): 972-977.

[20] Teng B, Khan K, Al-Najjar H. The utility of elastography visual features to predict nodal malignancy during EBUS-TBNA. Eur Respir J 2020. 56 (suppl 64): 2854.

[21] Ernst A, Feller-Kopman D, Becker HD, Mehta AC. Central airway obstruction. Am J Respir Crit Care Med 2004: 169(12): 1278-1297.

[22] Murgu SD, Egressy K, Laxmanan B, Doblare G, Ortiz-Comino R, Hogarth DK. Central Airway Obstruction: Benign Strictures, Tracheobronchomalacia, and Malignancy-related Obstruction. Chest 2016: 150(2): 426-441.

[23] Senitko M, Abraham G. Feasibility and safety of endoscopic microwave ablation for malignant central airway obstruction; a case series. Eur Respir J 2020. 56 (suppl 64): 1204.

[24] Sabath BF, Casal RF. Bronchoscopic ablation of peripheral lung tumors. J Thorac Dis 2019: 11(6): 2628-2638.

[25] Sun J, Xie F, Chen J, Zheng X. Late Breaking Abstract - Microwave ablation via a flexible catheter for the treatment of nonsurgical peripheral lung cancer: a pilot study. Eur Respir J 2020. 56 (suppl 64): 1571.
[26] Kuijvenhoven J, Livi V, Szlubowski A, Ninaber M, Korenvaar D, Stoger L, Widya R, Braun J, Van Boven W, Trisolini R, Annema J. Endobronchial Ultrasound (EBUS) for T4 staging in patients with resectable NSCLC. Eur Respir J 2020. 56 (suppl 64): 3473.

[27] Troy LK, Grainge C, Corte TJ, Williamson JP, Vallee MP, Cooper WA, Mahar A, Myers JL, Lai S, Mulyadi E, Torzillo PJ, Phillips MJ, Jo HE, Webster SE, Lin QT, Rhodes JE, Salamonsen M, Wrobel JP, Harris B, Don G, Wu PJC, Ng BJ, Oldmeadow C, Raghu G, Lau EMT. Cryobiopsy versus Open Lung biopsy in the Diagnosis of Interstitial lung disease alliance I. Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respir Med 2020: 8(2): 171-181.

[28] Higa K, Niwa T, Sato M, Sato Y, Sekine A, Kitamura H, Baba T, Iwasawa T, Takemura T, Ogura T. Risk factors of transbronchial cryobiopsy complications: A Retrospective Study of 500 Patients. Eur Respir J 2020. 56 (suppl 64): 1819.

[29] Daniels J, Nijman S, Ruiter G, Nossent E. Transbronchial lung cryobiopsy in interstitial lung disease: safety & learning curve. Eur Respir J 2020. 56 (suppl 64): 1190.

[30] Kalpakam H, Bhat R, Bansal S, Bajaj P, Mehta R. Transbronchial Lung Cryobiopsy (TBLC) for Interstitial Lung Disease (ILD) can be safely done in patients with multiple medical comorbidities. Eur Respir J 2020. 56 (suppl 64): 1580.

[31] Tomassetti S, Pavone M, Ravaglia C, Wells A, Vancheri C, Rosi E, Cavazza A, Colby T, Rossi G, Ryu J, Puglisi S, Arcadu A, Dubini A, Picicchi S, Lavorni F, Poletti V. Clinical management implications of histologic information provided by lung biopsy in the multidisciplinary evaluation of interstitial lung diseases. Eur Respir J 2020. 56 (suppl 64): 3780.

[32] Nishikiori H, Chiba H, Hirota K, Suzuki T, Honda S, Yama N, Ikeda K, Mori Y, Asai Y, Koyama N, Kuronuma K, Hatakenaka M, Takahashi H. Development of an artificial intelligence software to detect interstitial pneumonias. Eur Respir J 2020. 56 (suppl 64): 3761.

[33] Tibiletti M, Naish J, Heaton MJ, Waterton J, Hughes P, Eaden JA, Scekoh S, Chaudhuri N, Bruce I, Bianchi SM, Wild J, Parker G. Oxygen enhanced MRI biomarkers of lung function in interstitial lung diseases. Eur Respir J 2020. 56 (suppl 64): 4330.

[34] Eaden J, Chan H-F, Weatherley N, Bianchi S, Wild J. Regional hyperpolarised 129-xenon diffusion-weighted MRI in patients with IPF. Eur Respir J 2020. 56 (suppl 64): 4333.

[35] de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van ’t Westeinde S, Prokop M, Mali WP, Mohamed Hoesin FAA, van Ooijen PMA, Aerts JGJ, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020 Feb 6;382(6):503-513.

[36] National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409

[37] Calderwood C, Skyllberg E, Desai K, Moghal M, Banka R. Lung cancer screening – what does it mean for our practice? Eur Respir J 2020. 56 (suppl 64): 4712.

[38] Cui X, Zheng S, Heuvelmans M, Du Y, Sirorenkov G, Dorrius M, Veldhuis R, Oudkerk M, de Bock G, Van Ooijen P, Vliegenthart R, Ye Z. Validation of a deep learning-based computer-aided system for lung nodule detection in a Chinese lung cancer screening programme. Eur Respir J 2020. 56 (suppl 64): 4168.
Tanabe N, Sato S, Tanimura K, Shima H, Oguma T, Sato A, Muro S, Toyohior H. CT evaluations of erector spinae muscle, emphysema, and airway disease for predicting mortality in COPD. Eur Respir J 2020. 56 (suppl 64): 4913.

Laclus M, Kendall I, De Backer W, De Backer J. Ventilation-perfusion measures based on functional respiratory imaging (FRI) do correlate with exercise tolerance and PRO’s in COPD. Eur Respir J 2020. 56 (suppl 64): 2081.

Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol. 2020 Aug;30(8):4381-4389.

Zerka F, Vaidyanathan A, Guiot J, Deprez L, Danthine D, Canivet G, Stephane M, Eftaxia E, Henket M, Thys M, Lambin P, Tsoutzidis N, Miraglio B, Wlash S, Meunier P, Vos W, Leijenaar R, Lovinfosse P. Development and validation of an automated radiomic CT signature for detecting COVID-19. Eur Respir J 2020. 56 (suppl 64): 4152.

Fleischer J, Islam MT. Identifying and phenotyping COVID-19 patients using machine learning on chest x-rays. Eur Respir J 2020. 56 (suppl 64): 4151.

Manoharan B, Shafiq M, Dawar U, Elsheikh A, Pittman M. Chest radiography – a predictor of prognosis in COVID-19. Eur Respir J 2020. 56 (suppl 64): 2079.

Sabria PT, Molina-Molina M, Aso-González S, Díez-Ferrer M, Sabater-Riera J, Dorca-Sargatal J, Santos-Pérez, S., Suárez-Cuartin, G. Late Breaking Abstract: Lung ultrasound for severity assessment and outcome prediction of COVID-19 patients. Eur Respir J 2020. 56 (suppl 64): 2777.

Costantini A, Bostantzoglou C, Blum TG. ERS International Congress, Madrid, 2019: highlights from the Thoracic Oncology Assembly. ERJ Open Res 2020. 6: 00131-2020.

Sharshar R, El-Shimy W, Elbadry A, Elganzory S. Study of ultrasound guided transthoracic fine needle aspiration and core needle biopsy in the diagnosis of peripheral pulmonary lesions. Eur Respir J 2020. 56 (suppl 64): 2791.

Mei F, Bonifazi M, Rot, M, Zuccatosta L, Bedawi E, Mccracken D, Gasparini S, Rahman N. Diagnostic yield and safety of image-guided pleural biopsy: a systematic review and meta-analysis. Eur Respir J 2020. 56 (suppl 64): 2789.

Quarato C, Venuti M, Lacedonia D, Dimitri L, Simeon A, De Cosmo S, Del Colle A, Barbaro M F, Sperandeo M. Transthoracic shear wave elastography (SWE) in lung subpleural lesions: a preliminary report. Eur Respir J 2020: 2783.

Yousefifard M, Baikpour M, Ghelichkhani P et al. Screening Performance Characteristic of Ultrasonography and Radiography in Detection of Pleural Effusion; a Meta-Analysis. Emerg (Tehran) 2016. 4: 1-10

Psallidas I, Kalomenidis I, Porcel JM et al. Malignant pleural effusion: from bench to bedside. Eur Respir Rev 2016. 25: 189-198

Nozaki S, Shiroshta A, Tanaka Y, Luo, Y, Kataoka, Y, Nakashima, K. Utility of thoracic ultrasound for detecting malignant pleural effusion: a systematic review and meta-analysis. Eur Respir J 2020. 56 (suppl 64): 2786.

Jacobsen N, Konge L, Pietersen PI, Nolsoe C, Graumann O, Laursen CB. Clinical applications of contrast-enhanced thoracic ultrasound (CETUS) compared to standard reference tests: a systematic review. Eur Respir J 2020: 2785.

Parry S, Baldwin C, Granger C, Mayer K, Abo S, Paris M, Ntoumenopoulos G, Pastva A, El-Ansary D, Mourtzakis M, Sarwal A. How is ultrasound imaging being used to assess respiratory musculature? A systematic review. Eur Respir J 2020: 2979.
[55] Castro-Anon O, Hassan, M., Banka, R., Mercer, R., Bedawi, E., Rahman, N. Diaphragm ultrasound examination before and after fluid drainage in patients with malignant pleural effusion. Eur Respir J 2020: 2787.

[56] d'Hooghe J, Alvarez Martinez H, Pietersen PI, Laursen CB, Hersch N, Tarnoki AD, Walsh S, Annema J, Gompelmann D. ERS International Congress, Madrid, 2019: highlights from the Clinical Techniques, Imaging and Endoscopy Assembly. ERJ Open Res 2020; 6: 00116-2020.

[57] Long L, Zhao HT, Zhang ZY et al. Lung ultrasound for the diagnosis of pneumonia in adults: A meta-analysis. Medicine (Baltimore) 2017; 96: e5713

[58] Ebrahimi A, Yousefifard M, Mohammad Kazemi H et al. Diagnostic Accuracy of Chest Ultrasonography versus Chest Radiography for Identification of Pneumothorax: A Systematic Review and Meta-Analysis. Tanaffos 2014; 13: 29-40

[59] Bloise S, La Regina D., iovine, E., Latin, C, Nocolai A, Matera L, Di Mattia G, Petrarca L, Nenna R, Frassanito A, Mancino E, Midulla F. Lung ultrasound for diagnosis of community-acquired pneumonia in children: a comparison with chest x-ray. Eur Respir J 2020. 56 (suppl 64): 5287.

[60] Ciucu I, Marc M, Mircov FN, Dediu M, Pop L. Ultrasound pneumonia dimensions in children and inflammation. Eur Respir J 2020: 1154.

[61] Jones BP, Tay ET, Elikashvili I, Sanders JE, Paul AZ, Nelson BP, Spina LA, Tsung JW. Feasibility and safety of substituting lung ultrasonography for chest radiography when diagnosing pneumonia in children: a randomized controlled trial. Chest 2016; 150(1): 131-138.

[62] Delestrain C, Thouvenin G, Richard N, Madhi F, Berdah L, El Jurdi H, Clement A, Epaud R, Corvol H, Nathan N. Lung ultrasound in children with interstitial lung disease: a pilot study. Eur Respir J 2020. 56 (suppl 64): 5288.

[63] Maci F, Quarato C, Lacedonia D, Scioscia G, Tondo P, Giardinelli A, Giuffreda E, Barbaro MF, Sperandeo M. The role of transthoracic ultrasound in the study of interstitial lung disease: HRCT versus ultrasound pattern. Eur Respir J 2020. 56 (suppl 64): 2781.

[64] Abdullayeva Z, Aydogdu M, Öztürk E, Demirci NY, Türktas H, Köktürk N. Lung ultrasound and ultrasound elastography for diagnosis and follow-up of interstitial diseases. Eur Respir J 2020. 56 (suppl 64): 4176.

[65] Institute E. Top 10 Health Technology Hazards In, Expert Insights from Health Devices; 2020

[66] Radiologists RCo. Ultrasound training recommendations for medical and surgical specialties In; 2017

[67] Abdullah Q, Azam A, Ganaie MB. Thoracic ultrasound (TUS) training: regional survey of respiratory specialty trainees (RST) from West Midlands Deanery (WMD). Eur Respir J 2020. 56 (suppl 64): 4175.

[68] Society ER. Thoracic Ultrasound Certified Training Programme. In; 2019

[69] Society BT. National Safety Standards for Invasive Procedures (NatSSIPs) - Bronchoscopy and Pleural Procedures In. London: British Thoracic Society; 2018

[70] Abdullah Q, Khalil M, Ahmed M, Gulati A. Use of safety checklists for pleural procedures by respiratory trainees. Eur Respir J 2020. 56 (suppl 64): 2780.